Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia

RA Ducas, MD Seftel, J Ducas, C Seifer
2011 The Journal of the Royal College of Physicians of Edinburgh  
Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.
doi:10.4997/jrcpe.2011.204 pmid:21677914 fatcat:djfvcyur75bedkpkjwdyaynmoa